The xCures technology platform uses artificial intelligence (A.I.) and predictive modeling to identify and rank the most promising treatment options for advanced cancer patients who are not responding to standard of care therapies.

Patients pay with their data. They sign a HIPAA release giving xCures the right to request their medical records. The platform then provides these patients a personalized list of top treatment options and information about how to access them. 

The xCures platform captures Real World Evidence (RWE) from patients being treated in clinical trials, compassionate use and managed access programs, virtual and decentralized studies, investigator-initiated studies, and even N-of-1 clinical studies.

The RWE is used to accelerate the development of new drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement. The platform accepts records from any US-based institution, in any form, and compiles the data into a pan-cancer registry under an IRB-approved master protocol suitable for FDA submissions and medical publications.

xCures makes it possible to learn from the experiences of all patients who give us their data in return for treatment options, and optimize options selection for future patients.

The xCures technology platform uses artificial intelligence (A.I.) and predictive modeling to identify and rank the most promising treatment options for advanced cancer patients who are not responding to standard of care therapies.

Patients pay with their data. They sign a HIPAA release giving xCures the right to request their medical records. The platform then provides these patients a personalized list of top treatment options and information about how to access them. 

The xCures platform captures Real World Evidence (RWE) from patients being treated in clinical trials, compassionate use and managed access programs, virtual and decentralized studies, investigator-initiated studies, and even N-of-1 clinical studies.

The RWE is used to accelerate the development of new drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement. The platform accepts records from any US-based institution, in any form, and compiles the data into a pan-cancer registry under an IRB-approved master protocol suitable for FDA submissions and medical publications.

xCures makes it possible to learn from the experiences of all patients who give us their data in return for treatment options, and optimize options selection for future patients.

Cyclica operates in the exciting intersection of Technology and Life Sciences/Healthcare. Cyclica enhances drug discovery by harnessing big data and predictive analytics through it's patented cloud based platform, Ligand Express™ (www.ligandexpress.com). Traditional design of small molecule therapies has focused on specific, disease-associated protein targets which has led to the development of many breakthrough medicines. However, once a drug enters the body it interacts with dozens, if not hundreds, of proteins before it is excreted. These off-target interactions can represent threats to the safety of a drug, or potential repurposing opportunities. Cyclica harnesses biophysics, biological data, and artificial intelligence (AI) to help pharmaceutical companies navigate the drug discovery pipeline by assessing the safety and efficacy of drugs. Whether pre-clinical, clinical, or FDA approved, Cyclica's patented, drug-centric, structure-based and AI-augmented platform, Ligand Express™ , offers novel insight and analysis into a drugs’ poylpharmacology (i.e. all the proteins a drug interacts with). By focusing on a small molecule structure and its polypharmacological profile, we distinguish ourselves with virtual screening technologies that are specific for a protein structure. We further augment our structural information with AI to drive our biophysical simulations. Learn more through a short video: https://www.youtube.com/watch?v=pYtLKSZB-r0 or by visiting our website at https://cyclicarx.com/ligandexpress/. Our publications, validation notes, and case studies can be found here: https://cyclicarx.com/documentation/

Cyclica operates in the exciting intersection of Technology and Life Sciences/Healthcare. Cyclica enhances drug discovery by harnessing big data and predictive analytics through it's patented cloud based platform, Ligand Express™ (www.ligandexpress.com). Traditional design of small molecule therapies has focused on specific, disease-associated protein targets which has led to the development of many breakthrough medicines. However, once a drug enters the body it interacts with dozens, if not hundreds, of proteins before it is excreted. These off-target interactions can represent threats to the safety of a drug, or potential repurposing opportunities. Cyclica harnesses biophysics, biological data, and artificial intelligence (AI) to help pharmaceutical companies navigate the drug discovery pipeline by assessing the safety and efficacy of drugs. Whether pre-clinical, clinical, or FDA approved, Cyclica's patented, drug-centric, structure-based and AI-augmented platform, Ligand Express™ , offers novel insight and analysis into a drugs’ poylpharmacology (i.e. all the proteins a drug interacts with). By focusing on a small molecule structure and its polypharmacological profile, we distinguish ourselves with virtual screening technologies that are specific for a protein structure. We further augment our structural information with AI to drive our biophysical simulations. Learn more through a short video: https://www.youtube.com/watch?v=pYtLKSZB-r0 or by visiting our website at https://cyclicarx.com/ligandexpress/. Our publications, validation notes, and case studies can be found here: https://cyclicarx.com/documentation/